NEW YORK (GenomeWeb News) – PamGene International announced today that it has entered into a co-marketing pact with Invitrogen covering nuclear hormone receptor products.
 
Under the alliance, the firms will co-market Invitrogen’s nuclear hormone receptor proteins and Lanthascreen assay technology with PamGene’s microarray-based nuclear hormone receptor screening tools including its PamChip applications and PamStation instruments.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.